<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Inactivation of the CDKN2/p16(INK4A) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor gene is one of the most frequent genetic alterations in human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, mutations of the p16 gene or homozygous deletions of the gene locus 9p21 are rare </plain></SENT>
<SENT sid="2" pm="."><plain>This study investigated whether p16 promoter hypermethylation is an alternative mechanism for p16 gene inactivation during <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A methylation-specific polymerase chain reaction protocol was applied </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 95 specimens from 14 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> were analyzed longitudinally </plain></SENT>
<SENT sid="5" pm="."><plain>The p16 promoter status was compared with histomorphological findings </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: p16 promoter hypermethylation was detected in 9 of the 10 patients who had displayed <z:mpath ids='MPATH_589'>dysplasia</z:mpath> at some time during surveillance, whereas none of the patients who had not displayed <z:mpath ids='MPATH_589'>dysplasia</z:mpath> during surveillance had p16 promoter hypermethylation </plain></SENT>
<SENT sid="7" pm="."><plain>p16 promoter hypermethylation was detected in 3% (2 of 67) of the samples without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 60% (3 of 5) of the samples with lesions indefinite for <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 55.6% (10 of 18) of the specimens with low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and 75% (3 of 4) of the specimens with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: These data suggest that p16 promoter hypermethylation is a common mechanism of p16 gene inactivation during <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
</text></document>